Skip to main content
Download PDF

Correction: Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach

BMC Complementary Medicine and Therapies volume 24, Article number: 312 (2024) Cite this article

The Original Article was published on 05 October 2023

Correction: BMC Complement Med Ther 23, 352 (2023)

https://doi.org/10.1186/s12906-023-04171-w


A correction has been made to Fig. 5. The sub-image of GAPDH (the last western blot image of Fig. 5A) was replicated and incorrectly uploaded instead of the sub-image for COL5A2 (the first line of the Fig. 5A). This error does not affect the conclusion of the publication.

Fig. 5
figure 1

The expressions (A) and the statistics results (B) of COL5A2, LOX, and CTGF in the western blot analysis. *Represents the P < 0.05. The A549 cells (control group) were pretreated with 10ng/ml of TGF-β1 to build the in vitro IPF model, and then the cells were treated with 1.5μmol/l of swertiamarin (test group) for 24 h. The samples for determining the expressions of COL5A2, LOX, CTGF, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were derived from the same batch of experiments. The gels were processed in parallel

Full size image

The original article [1] has been corrected.

Reference

  1. Chang J, Zou S, Xiao Y, et al. Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach. BMC Complement Med Ther. 2023;23:352. https://doi.org/10.1186/s12906-023-04171-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Life Science, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, China

    Jun Chang, Shaoqing Zou, Yiwen Xiao & Du Zhu

Authors
  1. Jun Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaoqing Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiwen Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Du Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jun Chang or Du Zhu.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, J., Zou, S., Xiao, Y. et al. Correction: Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach. BMC Complement Med Ther 24, 312 (2024). https://doi.org/10.1186/s12906-024-04616-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12906-024-04616-w

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us